There were 7 patients recruited into the study 3 had stage II disease and 4 had stage IV disease. Both median PFS and OS were estimated using Kaplan-meier curves. OS was calculated from the start of treatment to the date of death or last follow-up. PFS was calculated from the start of treatment to the date of progression or last follow-up. #DOWNLOAD GIFOX FREE#The primary objective was to estimate the overall response rates (ORR) and the secondary objectives were to estimate the progression free survival (PFS), overall survival (OS) and toxicities of this regimen. Dose and schedule of G, If and Ox were 1000mg/m2 on day 1, 5g/m2 on day 2 and 85mg/m2 on day 2 respectively. Intravenous B was dosed at 1.3mg/m2 on days 1, 4, 8, and 11 every 21 days. Patients with advanced stage disease were treated with 6 cycles of B-GIFOX. Patients with stage IB/IX or II were treated with 4 cycles of B-GIFOX followed by radiotherapy. Patients with histologically confirmed NKTL with stage IB or bulky(X) and stage II-IV disease were included. This was an open-labelled prospective phase II study approved by the institutional review board. Hence we conducted a study to evaluate the clinical efficacy of B-GIFOX in patients with newly diagnosed NKTL. We have also previously published a patient with relapsed NKTL that was successfully treated with GIFOX therapy. Further, drug testing in mouse NKTL xenograft suggest gemcitabine (G), oxaliplatin (ox) and ifosfamide (if) were effective in inducing tumor regression. Bortezomib (B) is a potent and reversible proteasome inhibitor which has shown single agent activity in preclinical models of NKTL in vitro and in vivo. Gene expression profiling of NKTL revealed overexpression of NF-kB. Natural-killer/T-cell lymphoma (NKTL) is a subtype of non-Hodgkin's lymphoma with poor response to conventional chemotherapy.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |